Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | NA | High |
Rating | 3.0 | 4.0 |
Min SIP Amount | ₹250 | ₹100 |
Expense Ratio | 2.15 | 1.72 |
NAV | ₹29.61 | ₹75.31 |
Fund Started | 25 Jan 2010 | 16 Feb 2004 |
Fund Size | ₹27.30 Cr | ₹3188.48 Cr |
Exit Load | - | Exit load for units in excess of 30% of the investment,1% will be charged for redemption within 1 year |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 6.33% | 8.96% |
3 Year | 8.69% | 11.06% |
5 Year | 8.95% | 10.58% |
1 Year
3 Year
5 Year
Equity | 19.63% | 22.00% |
Cash | 38.34% | 5.10% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
---|---|
HDFC Bank Ltd. | 3.03% |
ICICI Bank Ltd. | 2.22% |
Reliance Industries Ltd. | 1.77% |
Bharti Airtel Ltd. | 1.70% |
HCL Technologies Ltd. | 1.11% |
Infosys Ltd. | 1.00% |
Axis Bank Ltd. | 0.87% |
State Bank of India | 0.77% |
ITC Ltd. | 0.61% |
Bharat Petroleum Corporation Ltd. | 0.58% |
Name | Assets |
---|---|
ICICI Bank Ltd. | 1.69% |
SBI Life Insurance Company Ltd. | 1.36% |
Maruti Suzuki India Ltd. | 1.13% |
Sun Pharmaceutical Industries Ltd. | 1.07% |
HDFC Bank Ltd. | 1.04% |
Axis Bank Ltd. | 0.94% |
NTPC Ltd. | 0.86% |
HDFC Life Insurance Co Ltd. | 0.82% |
Bharti Airtel Ltd. | 0.81% |
Gland Pharma Ltd. | 0.78% |
Name | Dwijendra Srivastava | Ritesh Lunawat |
Start Date | 03 Nov 2015 | 28 Dec 2020 |
Name
Start Date
Description | The scheme seeks to generate income and capital appreciation through investments predominantly in fixed income securities and in equity and equity related instruments. | The scheme seeks to generate long-term capital appreciation by investments in money market and debt instruments. |
Launch Date | 25 Jan 2010 | 16 Feb 2004 |
Description
Launch Date